Ocular Therapeutix, Inc. Completes Series D Financing To Support Phase II Sustained Drug Delivery Clinical Trials

Ocular Therapeutix, Inc. announced today that it has closed a $14 million Series D round of financing. The round was led by Ascension Health Ventures of St. Louis, Missouri, with continued participation by existing investors including Polaris Ventures, SV Life Sciences and Versant Ventures.

Full Story →